Objective: The current set of studies describe the in vivo metabolic actions of the novel amylin-mimetic peptide davalintide (AC2307) in rodents and compares these effects with those of the native peptide. Research design and methods: The anti-obesity effects of davalintide were examined after intraperitoneal injection or sustained peripheral infusion through subcutaneously implanted osmotic pumps. The effect of davalintide on food intake after lesioning of the area postrema (AP) and neuronal activation as measured by c-Fos, were also investigated. Results: Similar to amylin, davalintide bound with high affinity to amylin, calcitonin and calcitonin gene-related peptide receptors. Acutely, davalintide displayed greater suppression of dark-cycle feeding and an extended duration of action compared with amylin (23 versus 6 h). Davalintide had no effect on locomotor activity or kaolin consumption at doses that decreased food intake. Davalintide-induced weight loss through infusion was dose dependent, durable up to 8 weeks, fat-specific and lean-sparing, and was associated with a shift in food preference away from high-fat (palatable) chow. Metabolic rate was maintained during active weight loss. Both davalintide and amylin failed to suppress food intake after lesioning of the AP and activated similar brain nuclei, with davalintide displaying an extended duration of c-Fos expression compared with amylin (8 versus 2 h). Conclusion: Davalintide displayed enhanced in vivo metabolic activity over amylin while retaining the beneficial properties possessed by the native molecule. In vitro receptor binding, c-Fos expression and AP lesion studies suggest that the metabolic actions of davalintide and amylin occur through activation of similar neuronal pathways.
Introduction
Amylin is a peptide hormone synthesized by pancreatic b-cells that is co-secreted with insulin in response to nutrient intake. Its sequence is highly preserved across mammalian species, with structural similarities to calcitonin gene-related peptide (CGRP), calcitonins, intermedins and adrenomedullin. 1 The glucoregulatory actions of amylin complement those of insulin by regulating the rate of glucose appearance in the circulation through suppression of nutrient-stimulated glucagon secretion and by slowing gastric emptying. 2 In insulin-treated patients with diabetes, pramlintide, a synthetic and equipotent analog of human amylin, 3, 4 reduces postprandial glucose excursions by suppressing inappropriately elevated postprandial glucagon secretion and by slowing gastric emptying. [5] [6] [7] Amylin also reliably reduces food intake and body weight in rodents. Peripheral administration decreases food intake, 8 and among systemically administered anorexigenic molecules (amylin, salmon calcitonin, peptide YY 3-36, cholecystokinin-8, glucagon-like peptide-1, CGRP, adrenomedullin, leptin, the melanocortin agonist MTII, the cannabinoid receptor antagonist AM251 and naloxone), amylin receptor agonism demonstrates the greatest potency to inhibit consumption. 9 Amylin suppresses food intake by reducing meal size, 10, 11 while having no effect on conditioned taste aversion, 12, 13 kaolin consumption (a preclinical marker of emesis), 11 or locomotor activity, 11 suggesting a direct effect of the hormone on metabolic pathways. Amylin's action is mediated by activation of amylin-binding sites in the area postrema (AP) as lesioning this site abolishes its ability to reduce food intake. [14] [15] [16] c-Fos expression is observed in the AP after systemic amylin treatment, as well as in additional upstream pathways, including the nucleus tractus solitarii (NTS), lateral parabrachial nucleus (lPBN) and central amygdala. 17 Amylin has also been shown to reverse fastinginduced c-fos activation in the lateral hypothalamic area. 18 Endogenous amylin may contribute to the physiological control of food intake as amylin receptor antagonism stimulates feeding in normal, untreated animals. 19, 20 Chronic amylin infusion elicits sustained weight loss in high fat-fed/diet-induced obese rats, 11, 16, 21 with a selective reduction of fat mass. 11, 21 Mechanisms in addition to decreased energy intake may also contribute to this weight reduction. Amylin-treated rats maintain their metabolic rate despite a negative state of energy balance and weight loss 11, 21 and display decreased preference for high-fat (palatable) food. 11 Furthermore, the combination of amylin with other anorexigenic agents elicits additive (peptide YY , glucagon-like peptide 1 receptor agonism, phentermine and sibutramine) and even synergistic actions (leptin, cholecystokinin) to reduce food intake and body weight, illustrating the advantage of targeting multiple metabolic pathways to modulate body weight. [22] [23] [24] [25] Importantly, clinical studies confirm the potential of amylin receptor agonism to promote weight loss. For example, pramlintide significantly reduced body weight in patients with diabetes on insulin therapy, an intervention associated with weight gain. 26 Pramlintide also elicited significant weight loss in obese subjects in the absence of lifestyle intervention, 27, 28 and produced greater initial weight loss compared with placebo and longer maintenance of weight loss when used in conjunction with lifestyle intervention. 29 Although the therapeutic potential of amylin receptor agonism to stimulate weight loss has been clearly demonstrated, pramlintide and amylin have a short half-life (rat t 1/2 ¼ 13 min, human t 1/2 ¼ 20-45 min) and low bioavailability, resulting in multiple daily dosing that impacts patient compliance and cost per day of therapy (for review, see Roth et al. 30 ). We therefore identified regions of the amylin molecule amenable to modification in an attempt to improve duration of action, as well as efficacy, for weight loss. The current set of experiments describes the in vivo actions of the novel amylin-mimetic peptide davalintide (AC2307), which shares B49% amino-acid sequence homology with rat amylin and pramlintide (Table 1) , and show davalintide to possess improved pharmacological/pharmaceutical properties while maintaining the aforementioned beneficial attributes of native amylin. For injection studies, peptides were dissolved in 10% dimethylsulfoxide/water (1 ml kg À1 unless otherwise noted).
Research design and methods
Peptides delivered continuously through Alzet osmotic pumps (Durect Corporation, Cupertino, CA, USA) were dissolved in 50% dimethylsulfoxide/water. In all studies rat amylin was used; it is henceforth referred to as amylin. Amylin was synthesized by Peptisyntha (Torrance, CA, USA). Davalintide was prepared at Amylin Pharmaceuticals using FMOC (9H-fluorenyl-9-methoxycarbonyl) chemistry and solid-phase peptide synthesis. After trifluoroacetic acid cleavage from resin and oxidation to form the N-terminal disulfide, the crude peptide was purified by liquid chromatography-mass spectrometry and shown to be chromotographically pure by analytical high performance liquid chromatography. Cisplatin was supplied by Sigma-Aldrich (Saint Louis, MO, USA). As preliminary data suggested enhanced potency of davalintide, in some studies it was administered at a dose lower than amylin to attain a similar magnitude of effect with the two peptides.
In vitro studies For all receptor-binding studies, the tracer concentrations were chosen by running various tracer/membrane concen- ) and unlabeled peptides for 60 min at ambient temperature. Well contents were collected and plates counted as described above.
Calcitonin adenylate cyclase. Serially diluted peptides were transferred to an assay plate. Rat pancreas insulinoma cells (RINm5F) were detached from a tissue culture flask with Versene and washed once in buffer. Cells were re-suspended in buffer and cells were added to all wells of the assay plate. Cells and peptides were stimulated at room temperature in the dark for 30 min. The reaction was terminated with lysis buffer and incubated at room temperature for 4 h in the dark. Cyclic AMP content was measured (Perkin-Elmer AlphaScreen cAMP assay kit) and results were read (Perkin-Elmer Alpha Fusion fluorometer).
In vivo studies The effect of davalintide and amylin on food intake was first examined in overnight-fasting mice (24-30 g ). Cages were randomized into treatment groups (n ¼ 4 cages per peptide, n ¼ 12 cages per vehicle). All mice within a cage (n ¼ 3 per cage) received the same treatment. Mice received an intraperitoneal (IP) injection (200 ml) of peptide or vehicle, and food intake per cage was measured 30, 60 and 120 min post-injection. The effect of davalintide (1.09-1087 mg kg À1 ) and amylin (3.9-1176 mg kg À1 ) on food intake was examined in two separate experiments. Food intake was also examined during the dark phase in satiated rats. SD rats (394-461 g) maintained on a 45% fat kcal diet habituated to the feeding chamber and diet for 10 d. Animals received daily IP injections of vehicle 15 min prior to lights off, beginning day 7 of habituation. After the habituation period, animals were divided into treatment groups of equal food consumption. On test day, rats received an IP injection of davalintide (5 mg kg À1 ), amylin (6 mg kg À1 ) or vehicle 15 min prior to lights off (n ¼ 6 per group) and placed immediately into the feeding chamber. This apparatus consisted of a 13 Â 10 Â 9-inch plexiglass cage equipped with a tunnel containing a food hopper at the end. As the animal eats, the hopper is weighed at 1-min intervals (DietScan System, DietPro software, AccuScan Instruments, Columbus, OH, USA). Hourly food intake and body weight were measured at 23 h post-injection.
Locomotor activity, food intake and kaolin consumption were examined in SD rats (325-425 g). For activity testing, rats were divided into treatment groups of equal body weight, administered an IP injection of davalintide (1, 10 or 100 mg kg À1 ) or vehicle (n ¼ 7 per group), and immediately placed in activity monitors (Smart Frame Units, Kinder Scientific, Poway, CA, USA) for 30 min. Distance traveled was derived from the number of beam interruptions. Food intake was measured in a second group of overnight-fasted rats. Animals were divided into treatment groups of equal body weight, and received an IP injection of davalintide (1, 10 or 100 mg kg À1 ) or vehicle (n ¼ 7 or 8 per group). Food intake was measured 30 and 60 min post-injection. A third group of rats was introduced to kaolin pellets for 3 days before experimentation. On day 4, rats were divided into treatment groups of equal chow and kaolin intake. On day 5, chow and kaolin were removed just before lights were turned off. The next morning, rats received an IP injection of davalintide (1, 10 or 100 mg kg The metabolic effects of sustained davalintide infusion were examined in rats. After 6 weeks on a 32% fat kcal diet, diet-induced obese rats were divided into treatment groups of equal body weight (mean body weight ¼ 464 ± 6.7 g), and under anesthesia, surgically implanted subcutaneously (SC, in the intrascapular region) with 4-week pumps delivering continuous infusion of peptide. At 4 weeks, fresh 4-week pumps replaced the used pumps. Thus, rats received pumps delivering davalintide (1, 3, 10 or 100 mg kg À1 day
À1
) or vehicle continuously for 8 weeks. A pair-fed group received a vehicle pump, with each rat being fed each morning an amount of food equal to the mean intake of the 100-mg kg À1 day À1 group during the preceding 24 h (n ¼ 10 per group). At 8 weeks, blood was collected into heparinized syringes through cardiac puncture and triglyceride concen- In a second experiment, diet-induced obese rats fed a 32% fat kcal diet for 8 weeks were presented with a choice of standard chow or the 32-kcal% fat diet for 2 weeks. Animals (mean body weight ¼ 515±7 g) were divided into treatment groups of equal body weight and implanted SC with 4-week pumps delivering davalintide (10 mg kg À1 day
), amylin (300 kg À1 day À1 ) or vehicle (n ¼ 8 per group). As data suggested that davalintide is more potent and efficacious than amylin when administered via SC infusion, the doses were chosen in an attempt to attain a similar magnitude of the food intake effect with the two peptides. Animals had ad libitum access to both chows throughout the study. Food intake and body weight were measured weekly.
A third group of SD rats fed on a 32% fat kcal diet for 5 weeks (mean body weight ¼ 421 ± 3 g) were implanted SC with 4-wk pumps delivering davalintide (30 mg kg À1 day
), or vehicle (n ¼ 9 or 10 per group). Oxygen consumption (VO 2 ) and carbon dioxide production (VCO 2 ) were measured at the end of weeks 2 and 4 by indirect calorimetry (Oxymax Indirect Calorimetry System, Columbus Instruments, OH, USA). Animals acclimated to the test chambers, in the presence of food and water, 24 h before testing. On the following day, food was removed and 24-h VO 2 and VCO 2 measured. Fasted animals were used to gauge the metabolic rate more accurately without the confounding effects of differences in food intake between groups. Energy expenditure was calculated relative to body weight. The respiratory quotient (RQ) value was calculated as VCO 2 /VO 2 . Body weight and food intake were measured weekly.
Food intake was also examined in rats after AP lesion. Anesthetized SD rats (175-200 g) were placed in a stereotaxic apparatus, a midline incision made and the cervicoauricular and splenius muscles separated. A 'T'-shaped incision was made in the atlanto-occipital membrane situated at the base of the occipital bone to allow cerebral spinal fluid to escape. The AP was visualized using a dissecting microscope and aspirated with a blunt 26-g needle attached to a vacuum pump. The muscles were repositioned and affixed with absorbable cat gut, and the incision fastened with sutures. Sham surgeries were carried out in the same manner up to the point of releasing the cerebral spinal fluid and visualizing the AP. After surgery, animals were placed in a heated box and recovery monitored. Rats were fed moistened chow until weight gain was observed, but for no more than 7 days. AP-lesioned rats also received sweetened cereal during the first week post-surgery to encourage eating (Honey Nut Cheerios, General Mills, Minneapolis, MN, USA).
Food intake was measured at least 2 months post-surgery to ensure animals had reached or exceeded pre-surgery body weights (27-36 weeks of age). Animals were divided into treatment groups of equal body weight and fasted overnight. In experiment 1, sham and AP-lesioned rats received an IP injection (200 ml) of davalintide (10 mg kg 1C) and stained with thionin for analysis of lesion size and specificity. Two animals did not display full destruction of the AP (less than 95%) and were removed from analysis. c-Fos activation was examined in SD rats (400 g) maintained on a 32% fat kcal diet for 6 weeks before testing. Rats received an IP injection of davalintide (10 mg kg Brains were post-fixed overnight, placed in 30% sucrose for 24 h, frozen on dry ice and stored at À80 1C. Series of 30 mm sections were cut on a freezing microtome and immunohistochemistry performed on free-floating sections using previously published protocols. 17 Bright-field images were captured using a Leica DM5000 upright microscope (Leica Microsystems, Bannockburn, IL, USA) and a SPOT RT slider digital color camera using Spot Advanced Software (version 4.0.8, Diagnostic Instruments, Sterling Heights, MI, USA). Bright-field manual quantification of positive cells in each region was conducted. The brain areas prospectively selected for analysis included the AP, NTS, lPBN and central amygdala, regions previously identified to be activated by peripheral amylin administration. 17, 18 Group differences were assessed using analysis of variance followed by post hoc Dunnett's (comparison with vehicle) or Newman-Keuls multiple comparison tests. In one study, t-tests were used to compare the pair-fed group to vehicle. ED 50 values were generated using sigmoidal dose-response curves. Significance level was set at Po0.05. All data are presented as mean ± s.e.m.
Results
In vitro binding. Davalintide displayed similar potency to amylin at the amylin (nucleus accumbens) receptor IC 50 : davalintide ¼ 0.04, amylin ¼ 0.09 nM), was 10-fold more potent 
nM).
Acute food intake. Davalintide and amylin dose-dependently and significantly decreased food intake in fasted mice at the four highest doses tested (Figure 1a ). Davalintide and amylin also displayed similar potencies and magnitudes of food intake suppression (ED 50 ¼ 87 and 110 mg kg
À1
, respectively, maximal suppression ¼ 96%). In satiated rats, davalintide significantly reduced food consumption up to 23 h postinjection (Figure 1b) . At an equivalent dose, amylin significantly decreased food intake from 1-3 and 5-6 h post-treatment. Davalintide also significantly inhibited food intake to a greater extent than amylin from 2-23 h.
Locomotor activity, food intake and kaolin consumption. Davalintide up to 100 mg kg À1 had no effect on 30-min locomotor activity (Figure 2a ), whereas food intake was significantly reduced at 30 (100 mg kg
) and 60 min (10 and 100 mg kg Davalintide, a new amylin-mimetic peptide CM Mack et al cisplatin significantly decreased food intake and significantly increased kaolin consumption compared with vehicle, whereas davalintide (100 mg kg À1 ) significantly decreased food intake but did not elicit kaolin consumption (Figures 2c and d) .
Food intake and body weight with sustained infusion. Sustained davalintide infusion dose-dependently decreased food intake, body weight and fat mass. Throughout the course of the study, food intake was lower in davalintide-versus vehicletreated rats (Figure 3a) . Total food intake at 8 weeks was significantly lower at 3, 10 and 100 mg kg À1 day À1 doses compared with vehicle whereas there was no difference between the pair-fed and 100-mg kg À1 day À1 dose groups ( Figure 3b ; ED 50 at 4 and 8 weeks ¼ 2.0 and 1.3 mg kg À1 day À1 , respectively).
Body weight (% of initial) was significantly lower in all davalintide-treated groups compared with controls at 8 weeks (Figure 3c ; ED 50 at 4 and 8 weeks ¼ 1.2 and 1.1 mg kg À1 day À1 , respectively). The 100 mg kg À1 day À1 group lost significantly more weight than pair-fed rats (Figure 3c ). Vehicle-corrected weight loss was 10, 15, 22, 19 and 11%, in the 1, 3, 10, 100 mg kg À1 day À1 and pair-fed groups, respectively. Davalintide also significantly reduced fat mass and Food preference with sustained infusion. For total food intake (both diets combined), a two-way analysis of variance revealed a significant main effect of Treatment and a significant Treatment Â Week interaction (Figure 4a ). Both davalintide and amylin significantly reduced food consumption compared with controls, but did not differ from one other (total food intake at 4 weeks: davalintide ¼ 1626.5 ± 38.3, amylin ¼ 1701.4 ± 49.4, vehicle ¼ 2203.0 ± 65.4 g; Po0.05). With regard to high-fat intake, there was a significant main effect of Treatment for percent of high-fat calories consumed (Figure 4b ). In comparison with controls, consumption of the high fat diet was significantly reduced by davalintide and amylin, which in turn did not differ from one another (total percentage of high-fat calories consumed at 4 weeks: davalintide ¼ 85.3 ± 2.6, amylin ¼ 81.4 ± 3.8, vehicle ¼ 93.1 ± 2.5%; Po0.05).
Energy expenditure with sustained infusion. Neither davalintide nor amylin affected 24-h oxygen consumption compared with vehicle after 2 or 4 weeks of treatment, although body weight (% of initial) at each time point was significantly reduced by both peptides versus control (Table 2; vehicle-corrected body weight loss of 9 and 7% at 2 weeks and 11 and 9% at 4 weeks, respectively). The RQ value was modestly, but significantly increased with davalintide and amylin versus control at 2 but not 4 weeks ( Table 2 ). There were no significant differences between davalintide and amylin for any measure.
Food intake after AP lesioning. Lesion of the AP abolished the ability of both davalintide and amylin to reduce food intake. In sham animals, davalintide significantly reduced food intake up to 180 min compared with vehicle ( Figure 5a ). This effect was abolished in AP-lesioned rats: no difference in food intake was observed in AP-lesioned rats treated with davalintide compared with the sham-vehicle group (Figure 5b) . Similarly, in sham animals, amylin significantly reduced food intake at all time points compared with vehicle ( Figure 5c ), but had no effect in AP-lesioned rats (Figure 5d ). 
Discussion
The novel amylin-mimetic peptide davalintide displayed an extended duration of action to reduce food intake compared with amylin, and at the single doses tested also displayed increased potency for food intake suppression. Comparing davalintide's longer-term effects with amylin when administered via SC infusion 11 also suggests both greater potency and efficacy to reduce body weight in rats. The beneficial properties possessed by the native hormone were also retained: davalintide produced no off-target effects, weight loss was durable, dose-dependent and fat-specific, preference for palatable chow was reduced, and metabolic rate was maintained despite weight loss. Davalintide and amylin activated similar receptors in vitro, and both failed to reduce food intake after lesioning of the AP, suggesting activation of the same neuronal pathways. Indeed, davalintide induced c-Fos expression in regions identical to those activated by amylin and, importantly, extended the time-course of this activation.
Davalintide and amylin reduced food intake with similar potencies in mice. During dark-cycle feeding in rats, the duration of action and the magnitude of food intake suppression were increased with davalintide compared with amylin at the single dose tested. Recent data also show an extended duration of action of davalintide (up to 8 h), to delay gastric-emptying and reduce plasma glucose. 31 As observed with native amylin, 11 davalintide had no effect on locomotor activity or kaolin consumption at doses that decreased food intake, suggesting davalintide most likely reduced food intake through energy-homeostatic processes. Previous study has shown the anorexigenic effects of amylin to be mediated through the AP. [14] [15] [16] At doses producing equal magnitudes of food intake suppression, davalintide and amylin failed to decrease food intake in AP-lesioned rats, suggesting that, similar to amylin ( 17,18 and current study), the AP is also a critical brain nucleus mediating the anorexigenic action of davalintide. Sustained exposure of davalintide decreased body weight over 8 weeks and was associated with decreased fat mass and lean sparing, similar to previous reported effects with amylin. 11, 16, 21 The efficacy and potency of davalintide to reduce weight were similar at 4 and 8 weeks, indicating the durability of this effect. Comparison of these results to amylin under identical conditions 11 suggest enhanced , maximal weight loss ¼ 14%).
Davalintide produced greater fat loss and increased lean tissue compared with pair-fed animals, consistent with the effect of amylin in this model. 11, 21 In addition, the current data show that unlike amylin, davalintide also induced greater body weight loss compared with pair-fed animals. Additional mechanisms may thus also contribute to davalintide's metabolic actions. Under normal conditions, rats will reduce energy expenditure in response to fasting as a compensatory mechanism. Sustained infusion of amylin prevents this from occurring, 21 and similar effects were observed in this study with davalintide. Modest increases in RQ at week 2, but not week 4, in davalintide-and amylintreated rats is suggestive of a transient preference for carbohydrate versus fat utilization. As the animals were in the fasting state during calorimetry, this may reflect a prevention of a compensatory decline in RQ that occurs during food deprivation, rather than an increase in carbohydrate oxidation per se. Although a comprehensive longitudinal analysis of energy balance during weight loss in ad libitum fed animals, or in pair-fed/food-matched controls, was not performed, prevention of a compensatory reduction in energy expenditure (VO 2 ) during negative energy balance is a key feature of both amylin and davalintide. Changes in food preference may also contribute to body weight loss associated with amylin receptor agonism. Both davalintide and amylin durably decreased preference for high-fat (palatable) chow, replicating previously reported effects of amylin in this model 11 and consistent with decreased preference for sucrose after amylin 32 or salmon calcitonin 33 administration.
Although the precise receptor(s) mediating amylin's in vivo actions has not been elucidated, in vitro studies show amylin binds to specific amylin receptors that emerge from the dimerization of the calcitonin receptor with receptor activity modifying proteins (RAMP1, RAMP2 or RAMP3; for reviews, see Hay et el. 34 ;Sexton et al. Davalintide, a new amylin-mimetic peptide CM Mack et al binding potency at the amylin (nucleus accumbens) receptor, displayed 10-fold greater potency at the CGRP receptor, and was equally potent in mediating calcitonin receptor-mediated cyclic AMP production. Davalintide did exhibit a 100-fold greater binding potency at the calcitonin receptor, providing one explanation for the enhanced pharmacology of davalintide. The extended duration of action of davalintide may result from changes in pharmacokinetic properties, or alternatively, slower dissociation from its receptor, thus extending receptor activation and subsequently in vivo duration of action, a process that has been shown in vitro using the amylin agonist salmon calcitonin. 36 We hypothesized that the increased duration of action of davalintide may be explained by changes in neuronal activation. Although the lesioning data identified the AP as being necessary for the expression of davalintide's anorexigenic effects, davalintide could recruit similar or dissimilar neural pathways as native amylin on binding in the AP, and maintain their activation for a longer duration. Our c-Fos results clarified that davalintide activates a neural circuit similar to that of native amylin, but activates this circuit to a greater extent and for an extended period of time. Future studies will address whether davalintide recapitulates amylin's action to reverse fasting-induced neural activation, 17 reduce orexigenic gene expression, 37 restore central leptin sensitivity 24 or produce additive or synergistic action with other weight-loss agents. [22] [23] [24] [25] Pramlintide, the synthetic amylin analog, reduces food intake 28, 38 and body weight [27] [28] [29] in obese subjects. Translational medicine studies have recently revealed suppression of 24-h food intake in obese humans treated with davalintide, 39 providing proof-of-concept for the therapeutic potential of this analog. As demonstrated in both preclinical and clinical studies, amylin receptor agonism has emerged as a key component of an integrated neurohormonal therapeutic approach for weight reduction and maintenance that harnesses synergies among naturally occurring signals. 24, 40 The current data suggest that the enhanced pharmacological actions of the novel amylin-mimetic davalintide may provide additional benefit, as monotherapy or in combination, to enhance weight loss in the human population.
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